Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine

What Was Tested

This randomized controlled trial paper looks at CGRP (Calcitonin Gene-Related Peptide) in the context of migraine.

Who Took Part

The study group was 2076 patients.

Anti-drug antibody (ADA) results were available from 2074 of these patients.

Patients who had a confirmed ADA-positive result at the end-of-study visit were monitored for up to 6 additional months.

How the Study Was Run

The design is described as randomized, double-blind, open-label and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got CGRP (Calcitonin Gene-Related Peptide) and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on CGRP (Calcitonin Gene-Related Peptide), so expectations could not easily colour the readings.

Nothing was hidden in this open-label CGRP (Calcitonin Gene-Related Peptide) study: the patients and staff both knew the treatment.

Some patients received a placebo instead of CGRP (Calcitonin Gene-Related Peptide), giving a reference point.

A time span of 56 weeks appears in the methods.

Four studies were randomized, double-blind, placebo-controlled trials with ADA monitoring for up to 56 weeks; one was a 2-year, open-label, phase 3 safety study with ADA monitoring for 104 weeks.

What Was Measured

The subject headings attached to it are Antibodies, Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide and Migraine Disorders.

Author keywords: anti-drug antibody, calcitonin gene-related peptide (CGRP), eptinezumab, immunogenicity, monoclonal antibody and neutralizing antibody.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of CGRP (Calcitonin Gene-Related Peptide) in 2076 patients in people with migraine over 56 weeks.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Frontiers in immunology), a journal based in Switzerland.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.